Credit Suisse’s Benitec Biopharma BNTC Stock Holding History

Credit Suisse’s Portfolio BNTC Stock Details BNTC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-916	Closed	-$47K	–	4300
2020 Q4	$47K	Hold	916	–	–	﹤0.01%	4258
2020 Q3	$98K	Buy	+916	New	+$110K	﹤0.01%	3923

Other funds holding BNTC

HAG

HighPoint Advisor Group Downers Grove, Illinois $2.39B AUM 28.86% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

WealthTrust Axiom Wayne, Pennsylvania $406M AUM 40.44% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

SFI

Susquehanna Fundamental Investments Bala Cynwyd, Pennsylvania $2.67B AUM 21.74% 1-Year Est. Return

Credit Suisse's BNTC Position: Q1 2021 in Review

Credit Suisse sold out of Benitec Biopharma (BNTC) in Q1 2021, closing a stake of 916 shares — an estimated $47K sold.

Credit Suisse first reported a position in BNTC in Q3 2020 and held it in 2 quarters. The position peaked at $98K in Q3 2020. 14 funds tracked by Wall St. Rank hold BNTC as of Q1 2021.

Credit Suisse reported no remaining Benitec Biopharma position as of Q1 2021 after selling out during the quarter.
Credit Suisse sold 916 Benitec Biopharma shares in Q1 2021, an estimated $47K.
Credit Suisse first reported a position in Benitec Biopharma in Q3 2020 and held it in 2 quarters.
Credit Suisse's Benitec Biopharma position peaked at $98K in Q3 2020.
14 funds tracked by Wall St. Rank held Benitec Biopharma as of Q1 2021.

Based on Credit Suisse's 13F filing for Q1 2021, filed 14 May 2021.